Alecensa 150MG Capsule (7’s) is a targeted therapy medication that contains Alectinib, a potent anaplastic lymphoma kinase (ALK) inhibitor. This drug is primarily used in the treatment of non-small cell lung cancer (NSCLC) that is ALK-positive, which means that the cancer cells have a specific genetic alteration that makes them susceptible to this treatment. Each capsule contains 150 mg of Alectinib, designed to inhibit the growth of cancer cells by blocking the activity of the ALK protein, which plays a crucial role in the proliferation of these cells. Alecensa is typically prescribed for patients who have previously been treated with crizotinib or for those whose cancer has progressed on this medication. The formulation is designed for oral administration, making it convenient for patients to incorporate into their daily routines. As a result, Alecensa has become an essential option in the management of advanced ALK-positive NSCLC, offering hope for improved outcomes and quality of life for patients battling this challenging disease.